Free Trial
Memorial Day Savings! Save $100 on MarketBeat All Access
Claim Your Discount
Claim MarketBeat All Access Sale Promotion
NASDAQ:INAB

IN8bio Q3 2025 Earnings Report

IN8bio logo
$1.67 -0.01 (-0.60%)
Closing price 04:00 PM Eastern
Extended Trading
$1.65 -0.02 (-1.20%)
As of 04:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

IN8bio EPS Results

Actual EPS
-$0.85
Consensus EPS
-$1.20
Beat/Miss
Beat by +$0.35
One Year Ago EPS
N/A

IN8bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

IN8bio Announcement Details

Quarter
Q3 2025
Date
11/6/2025
Time
Before Market Opens
Conference Call Date
Thursday, November 6, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

IN8bio's Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 7, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

IN8bio's Q3 2025 Earnings ReleaseEarnings Release
(8-K)
IN8bio's Q3 2025 Quarterly ReportQuarterly Report
(10-Q)

IN8bio Earnings Headlines

IN8bio, Inc: IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 8, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68436859-in8bio-inc-in8bio-reports-first-quarter-2026-financial-results-and-recent-business-highlights-399.htm
IN8bio Reports Q1 2026 Results and Shareholder Votes
May 7, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/in8bio-reports-q1-2026-results-and-shareholder-votes?utm_source=marketbeat.com&utm_medium=referral
SpaceX controls two-thirds of all satellites - and it is about to go public
SpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June 4th. The company recently issued a 5-for-1 stock split, dropping shares from $526 to roughly $105 - a deliberate move to open access to everyday investors. SpaceX controls two-thirds of all satellites in orbit, accounts for 85% of global rocket launches, and has collected $13 billion from NASA over the past decade. Analyst Matt McCall has spent months researching how investors can get a stake before the IPO through a regular brokerage account, for less than $100.tc pixel
May 22 at 1:00 AM  |  NXT Wave Research (Ad)
IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/07/3290667/0/en/in8bio-reports-first-quarter-2026-financial-results-and-recent-business-highlights.html
IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences
May 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/06/3288735/0/en/in8bio-to-showcase-next-generation-t-cell-engager-platform-and-new-clinical-data-at-upcoming-r-d-day-and-medical-conferences.html
IN8bio (INAB) Gets a Buy from JonesTrading
April 16, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/INAB/pressreleases/1185317/in8bio-inab-gets-a-buy-from-jonestrading/
See More IN8bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IN8bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IN8bio and other key companies, straight to your email.

About IN8bio

IN8bio (NASDAQ:INAB) is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel γδ T cell engager platform, INB-600, which activates and expands γδ T cells in vivo for deep target cell depletion and is being developed for oncology and autoimmune indications.

View IN8bio Profile
Earnings Tools